Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + epacadostat + platinum doublet chemotherapy versus platinum doublet chemotherapy in first-line stage IV or recurrent NSCLC
2017-003304-43Phase 3Terminated
- Sponsor
- Incyte
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and epacadostat in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Incyte. Primary endpoints: Overall survival and Progression-free survival. Started Mar 2018; status: terminated.
02
Drugs
nivolumabepacadostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003304-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003304-43.